Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$82,437.00+0.02%ETH$2,488.81-1.91%GOLD$4,203.90+1.13%OIL$90.51-1.07%
Smart Investors Daily
SID Premium
ME

NASDAQ · MENS

Jyong Biotech Ltd. Ordinary Shares

Healthcare · Biotechnology

$2.10

Up+$0.04 (+1.94%)

Updated Oct 9, 2026, 11:16 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.04B
P/E ratio
-813.48
Dividend yield
0.00%
52-week range
$1.50 – $3.00
Volume
39.25K
Avg. volume
352K

Price performance · MENS

MENS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

MENS closed at $2.10 after 21 trading sessions, up 4.48% for the selected period.

Last close
$2.10
Period change
+4.48%
Period low
$1.97
Period high
$2.38
Daily close
View OHLC price history
MENS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$2.06$2.12$2.00$2.1039.25K
Oct 7, 2026$2.07$2.10$2.01$2.0626.84K
Oct 6, 2026$2.05$2.188$2.02$2.0220.19K
Oct 5, 2026$2.19$2.20$2.02$2.0547.37K
Oct 2, 2026$2.06$2.18$2.05$2.1829.81K
Oct 1, 2026$2.01$2.0795$1.97$2.0331.27K
Sep 30, 2026$2.02$2.078$1.92$2.0531.33K
Sep 29, 2026$2.07$2.07$1.96$2.0317.15K
Sep 28, 2026$2.08$2.118$1.94$1.9746.42K
Sep 25, 2026$2.268$2.268$2.03$2.0338.11K
Sep 24, 2026$2.275$2.33$2.06$2.1556.13K
Sep 23, 2026$2.23$2.378$2.1201$2.1468.75K
Sep 22, 2026$2.05$2.40$2.05$2.38121.28K
Sep 21, 2026$1.98$2.2298$1.98$2.15138.95K
Sep 18, 2026$2.166$2.20$2.06$2.0619.7K
Sep 17, 2026$2.04$2.22$2.04$2.0848.02K
Sep 16, 2026$2.198$2.1995$2.02$2.0627.55K
Sep 15, 2026$2.1124$2.20$2.055$2.1236.54K
Sep 14, 2026$2.06$2.13$2.03$2.0837.92K
Sep 11, 2026$1.98$2.055$1.98$1.9945.35K
Sep 10, 2026$2.15$2.195$1.965$2.0168.51K

Latest MENS news

The latest Smart Investors Daily articles mentioning MENS.

Stock researchCompany · Overview

MENS research

Overview

Company profile and research snapshot.

Company profile

Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 13, 2026

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the conver

defenseworld.net · Dec 8, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech's (NASDAQ: MENS - Get Free Report) lock-up period is set to end on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its IPO on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. Shares of the company owned by major shareholders and company

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By